Dimensional Fund Advisors LP Increases Position in IDEAYA Biosciences, Inc. $IDYA

Dimensional Fund Advisors LP increased its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 42.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,333,478 shares of the company's stock after purchasing an additional 394,621 shares during the quarter. Dimensional Fund Advisors LP owned 1.52% of IDEAYA Biosciences worth $44,418,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in IDYA. GSK plc acquired a new position in IDEAYA Biosciences during the fourth quarter worth $46,093,000. State Street Corp raised its position in IDEAYA Biosciences by 27.6% during the fourth quarter. State Street Corp now owns 4,134,641 shares of the company's stock worth $142,935,000 after acquiring an additional 893,707 shares during the last quarter. Janus Henderson Group PLC lifted its stake in IDEAYA Biosciences by 11.8% in the 4th quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company's stock valued at $248,344,000 after buying an additional 758,117 shares in the last quarter. First Turn Management LLC acquired a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at $25,017,000. Finally, Fiera Capital Corp grew its holdings in shares of IDEAYA Biosciences by 32.6% during the fourth quarter. Fiera Capital Corp now owns 2,437,262 shares of the company's stock worth $84,256,000 after buying an additional 599,295 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

Insiders Place Their Bets

In other news, CAO Briseno Andres Ruiz sold 9,550 shares of the company's stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the transaction, the chief accounting officer owned 26,466 shares in the company, valued at $1,058,904.66. This represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 4.70% of the company's stock.

Analysts Set New Price Targets

IDYA has been the subject of several analyst reports. Guggenheim upped their target price on IDEAYA Biosciences from $50.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, April 14th. Mizuho cut their price objective on IDEAYA Biosciences from $52.00 to $50.00 and set an "outperform" rating on the stock in a research report on Thursday, May 7th. Wells Fargo & Company boosted their target price on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 14th. Wall Street Zen raised shares of IDEAYA Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, June 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of IDEAYA Biosciences in a research note on Friday, July 17th. Fourteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $50.25.

IDEAYA Biosciences Price Performance

IDYA opened at $35.50 on Monday. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of -22.19 and a beta of -0.09. The business has a 50 day moving average price of $33.69 and a two-hundred day moving average price of $32.65. IDEAYA Biosciences, Inc. has a 1-year low of $22.09 and a 1-year high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analysts' expectations of $5.04 million. During the same period last year, the firm earned ($0.82) EPS. The business's quarterly revenue was down 39.4% compared to the same quarter last year. Equities analysts expect that IDEAYA Biosciences, Inc. will post -4.1 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.